Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 7

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 7
---
 any third-party information. In addition, projections, assumptions and estimates
of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk
due to a variety of factors, including those described in “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” These and other factors could cause results to differ materially from those expressed in the estimates made by
the independent parties and by us.

You should assume that
the information in this Prospectus is accurate only as of the date on the front of the document and that any information we have incorporated
by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this Prospectus
or any sale of securities.

<div align='center'>ii

GLOSSARY OF TECHNICAL TERMS USED</div>

The following are the meanings to be ascribed
to technical terms used throughout the prospectus.

“Antimicrobial Resistance (AMR)”
is the ability of microorganisms (bacteria, viruses, fungi, and parasites) to resist the effects of medications that once could successfully
treat them, leading to reduced treatment efficacy and increased health risks.

“Angiotensin II Type 1 Receptor (AT1)” refers to a
receptor involved in the renin-angiotensin system that regulates blood pressure and fluid balance; it also plays a role in tumor biology
and fibrosis.

“Ceramide Carbamoyl Spermine (CCS)”
is a synthetic cationic lipid composed of a ceramide backbone linked to a spermine-derived polyamine. CCS is used in advanced drug delivery
systems, particularly liposomal and nanoparticle formulations, for its ability to enhance cellular uptake and facilitate endosomal escape.
Its structure enables strong interaction with negatively charged cell membranes, making it especially effective for delivering nucleic
acids and other therapeutic payloads into target cells.

“Drug-Resistant Neisseria gonorrhoeae” is a common sexually transmitted infection caused by Neisseria gonorrhoeae, has become increasingly resistant
to nearly all antibiotics previously used to treat it. Certain strains now show resistance to extended-spectrum cephalosporins, the last
remaining recommended treatment, raising urgent public health concerns over the potential for untreatable infections.

“Excipients are inactive substances
included in drug formulations to aid in the manufacturing process, drug stability, or delivery, without exerting therapeutic effects.

“Extracellular Matrix